On December 13, 2021 Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, reported data from an ongoing pivotal Phase 2 study (CIBI376A201) evaluating parsaclisib, an potent, highly selective, next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ), for the treatment of patients with relapsed or refractory follicular lymphoma in China (Press release, Innovent Biologics, DEC 13, 2021, View Source [SID1234596985]). These data were presented at the 63rd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition (ASH 2021), held virtually from December 11–14, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The CIBI376A201 study is a multi-center, single-arm, open-label pivotal Phase 2 study conducted in China evaluating parsaclisib as a treatment for patients with relapsed or refractory follicular lymphoma. The primary endpoint is objective response rate (ORR) as assessed by independent review committee (IRC); duration of response (DOR), progression-free survival (PFS), overall survival (OS), safety and tolerability are among the secondary endpoints as assessed by investigators.

Eligible patients received parsaclisib 20 mg once daily for eight weeks followed by 2.5 mg once daily, till disease progression or intolerable adverse events. By the data cut-off date, 36 patients were enrolled, of which 24 were evaluable.

Key results of this study are: In 24 evaluable patients with r/r FL, ORR is 91.7% (95%CI : 73%, 99%), Complete Response(CR) is 16.7%, and Partial Response (PR) is 75%. As the results showed, parsaclisib was generally well tolerated with a manageable safety profile.

"We are glad that the data from study CIBI376A201 appears promising, which indicates the potential of parsaclisib to become a clinically valuable treatment for patients with relapsed or refractory follicular lymphoma," said Dr. Hui Zhou, Vice President of Innovent, "We hope the results of this study may potentially provide a new treatment option and help benefit those patients in China."

The leading PI of the study, Dr. Weili Zhao of Shanghai Jiaotong University Ruijin Hospital, stated "The interim analysis shows good response and a tolerable safety profile of parsaclisib in FL patients. We look forward to more exciting results to be revealed with the potential for parsaclisib to be a new effective treatment option for doctors to tackle relapsed or refractory follicular lymphoma."

Presentations are available on the ASH (Free ASH Whitepaper) website at: View Source

About Follicular Lymphoma

Follicular lymphoma is a B-cell cancer that originates from the uncontrolled division of specific types of B-cells known as centrocytes and centroblasts. Although it is classified as indolent lymphoma, and the current immunochemotherapy has achieved good efficacy, it still often relapses following by aggressive diseases, which may lead to death within 1 to 2 years. There is an unmet medical need for treatment options for recurrent/refractory follicular lymphoma.

About Parsaclisib

Parsaclisib is a potent, highly selective, next-generation investigational novel oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ). It is currently under evaluation as a monotherapy in several ongoing Phase 2 trials as a treatment for non-Hodgkin lymphomas (follicular, marginal zone and mantle cell); and autoimmune hemolytic anemia. Pivotal trials of parsaclisib in combination with ruxolitinib for the treatment of patients with myelofibrosis are underway; and there are plans to initiate a trial to evaluate parsaclisib in combination with tafasitamab for B-cell malignancies.

In December 2018, Innovent and Incyte entered into a strategic collaboration for three clinical-stage product candidates, including parsaclisib (PI3Kδ inhibitor). Under the terms of the agreement, Innovent has received the rights to develop and commercialize parsaclisib and two other assets in Mainland China, Hong Kong, Macau and Taiwan.